Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Not Yet Opened 12-20 16:00:00 EST

54.74

+0.68

+1.25%

High55.22	Low53.90	Vol1.77B
Open54.06	D1 Closing54.06	Amplitude2.44%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O28.99B	T/O Rate--	Tradable Shares0.00
P/B5.28569	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":54.736164,"timestamp":1734728399999,"preClose":54.060635,"halted":0,"volume":1769961383,"delay":0,"changeRate":0.012496,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":0.675529,"latestTime":"12-20 16:00:00 EST","open":54.0592,"high":55.223816,"low":53.903618,"amount":28991387778.53487,"amplitude":0.024421,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.28569,"peRate":-50.221891,"turnoverRate":0.055983,"increases":349,"decrements":216,"flats":14,"marketCap":1412634031658.125,"floatMarketCap":1271564946818.4375},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"2493202570","title":"Halozyme Therapeutics Inc : JP Morgan Raises Target Price to $55 From $54","url":"https://stock-news.laohu8.com/highlight/detail?id=2493202570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493202570?lang=en_us&edition=fundamental","pubTime":"2024-12-23 12:35","pubTimestamp":1734928551,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NL194:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"2493571204","title":"Vertex Pharmaceuticals Inc : Scotiabank Raises Target Price to $430 From $426","url":"https://stock-news.laohu8.com/highlight/detail?id=2493571204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493571204?lang=en_us&edition=fundamental","pubTime":"2024-12-23 12:10","pubTimestamp":1734927036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO02V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4567","LU2236285917.USD","IE00BJT1NW94.SGD","IE00B19Z9Z06.USD","LU0079474960.USD","LU2462157665.USD","LU0289739699.SGD","IE00B894F039.SGD","BK4532","LU0058720904.USD","LU0889565916.HKD","LU2362541513.USD","LU2362540622.SGD","LU0234570918.USD","LU1035775433.USD","LU1430594728.SGD","IE0002270589.USD","IE00B19Z9P08.USD","IE00BJJMRZ35.SGD","LU0256863811.USD","LU0417517546.SGD","LU1093756325.SGD","BK4585","VRTX","BK4533","LU2362541273.HKD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0109394709.USD","LU2456880835.USD","LU0823416689.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","LU1093756168.USD","IE00B2B36J28.USD","LU2417539215.USD","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BZ9MQY76.HKD","BK4139","LU1069344957.HKD","LU0061475181.USD","LU0320765992.SGD","BK4588","LU2237438978.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"2493095242","title":"Keros Therapeutics Inc : Truist Securities Cuts Target Price to $43 From $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2493095242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493095242?lang=en_us&edition=fundamental","pubTime":"2024-12-23 11:37","pubTimestamp":1734925065,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KROS"],"gpt_icon":0},{"id":"2493520692","title":"US FDA Approval of Mesenchymal Stromal Cell Therapy Bodes Well for Cynata Therapeutics, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2493520692","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493520692?lang=en_us&edition=fundamental","pubTime":"2024-12-23 11:19","pubTimestamp":1734923952,"startTime":"0","endTime":"0","summary":"The US Food and Drug Administration's approval of a mesenchymal stromal cell (MSC) therapy bodes well for Cynata Therapeutics (ASX:CYP), Euroz Hartleys said in a Dec. 19 note.Cynata Therapeutics focus","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","LENZ","CYP.AU","MSB.AU","BK4575","BK4150","BK4139","BK7067","MSC","BK7508"],"gpt_icon":0},{"id":"2493204334","title":"Exploring Undiscovered Gems with Potential This December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2493204334","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493204334?lang=en_us&edition=fundamental","pubTime":"2024-12-23 11:06","pubTimestamp":1734923163,"startTime":"0","endTime":"0","summary":"As December 2024 unfolds, global markets are navigating a complex landscape marked by cautious Federal Reserve commentary and political uncertainties, with smaller-cap indices experiencing notable declines. The Fed's recent rate cut and tempered expectations for future reductions have added to investor apprehension, impacting market sentiment across the board. In this environment, identifying stocks with strong fundamentals and resilience becomes crucial. Such undiscovered gems can offer potential opportunities amid broader market volatility by demonstrating robust financial health and adaptability to changing economic conditions.Overview: The Mediterranean and Gulf Cooperative Insurance and Reinsurance Company operates in the Kingdom of Saudi Arabia, offering a range of insurance and reinsurance products, with a market capitalization of SAR 2.37 billion.Click here to discover the nuances of Mediterranean and Gulf Cooperative Insurance and Reinsurance with our detailed analytical healt","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-undiscovered-gems-potential-december-030603358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","KMDA"],"gpt_icon":0},{"id":"2493627007","title":"Exploring High Growth Tech Stocks This December 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2493627007","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493627007?lang=en_us&edition=fundamental","pubTime":"2024-12-23 10:02","pubTimestamp":1734919371,"startTime":"0","endTime":"0","summary":"As global markets navigate a period of uncertainty marked by the Federal Reserve's cautious stance on interest rates and political tensions in the U.S., small-cap stocks have experienced notable volatility, with indices like the S&P 600 feeling the pressure. In this environment, identifying high growth tech stocks requires a focus on companies that demonstrate resilience through strong fundamentals and innovative potential, positioning them to capitalize on emerging opportunities despite broader market challenges.Click here to discover the nuances of Dynavox Group with our detailed analytical health report.Explore historical data to track Dynavox Group's performance over time in our Past section.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/q35t3.sfk5kqinfvQ0WIRA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/068a03d55fb1c2bd39157a1a3ff91964","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/q35t3.sfk5kqinfvQ0WIRA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/068a03d55fb1c2bd39157a1a3ff91964"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-020251107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","PBBIF","VAQC","BK4561","TDVXF"],"gpt_icon":0},{"id":"2493234277","title":"MicroStrategy Welcomes Former Binance.US CEO Brian Brooks to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2493234277","media":"CoinMarketCap","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493234277?lang=en_us&edition=fundamental","pubTime":"2024-12-23 09:24","pubTimestamp":1734917087,"startTime":"0","endTime":"0","summary":"Bitcoin advocate Michael Saylor’s MicroStrategy has appointed former Binance.US CEO Brian Brooks, along with two other executives, to its board of directors.This announcement follows Nasdaq’s recent decision to include MicroStrategy in the Nasdaq-100 index.Brooks, Jane Dietze — who also serves on Galaxy Digital’s board — and Gregg Winiarski, chief legal officer at Fanatics Holdings, join the board, increasing its total membership to nine, according to a Dec. 20 filing with the United States Securities and Exchange Commission .Swan Bitcoin highlighted the significance of Brooks’ appointment in a Dec. 21 X post, calling it a “BIG deal.”Brooks, who stepped down as CEO of Binance.US in August 2021 after citing “differences over strategic direction,” also served as Acting Comptroller of the Currency for nine months in 2021.Crypto commentator MacroScope shared with their 77,200 X followers, “all three are good especially Brooks.”MicroStrategy’s inclusion marks its position among the Nasdaq’s","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/f2b2128099694b4793c74b1452c29586.jpeg","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/f2b2128099694b4793c74b1452c29586.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6768bbe20514eb01620aa2fc/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["QID","BK4547","BK4170","BK4533","LU1267930730.SGD","BK4516","MNQmain","NVIW.SI","LU1169589451.USD","BK4594","USJW.SI","LU0672654240.SGD","LU1861220033.SGD","BK4534","BK4501","BK4595","SQQQ","BK4601","BK4600","BTC.USD.HKCC","MSTR","LU0053671581.USD","TSYW.SI","BK4121","PSQ","BK4535","BK4568","BK4596","NQmain","LU0109391861.USD","LU1169590202.USD","ILMN","BK4588","LU0708995401.HKD","LU1861559042.SGD","TQQQ","BK4548","BK4139","BK4551","USAW.SI","QLD","AXON",".IXIC"],"gpt_icon":1},{"id":"2493565270","title":"Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493565270","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493565270?lang=en_us&edition=fundamental","pubTime":"2024-12-23 09:20","pubTimestamp":1734916858,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Revance Therapeutics (RVNC – Research Report) and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revance-therapeutics-rvnc-and-neurocrine-nbix?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revance-therapeutics-rvnc-and-neurocrine-nbix?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","BK4585","LU0320765992.SGD","LU2065171402.SGD","LU2065171311.SGD","NBIX","BK4139","BK4137","LU2324357040.USD","LU0053671581.USD","LU2065169927.USD","BK4007","LU0823416689.USD","LU2065170008.USD","BK4588","RVNC","LU0889565916.HKD","HCSG"],"gpt_icon":0},{"id":"2493719652","title":"Chimeric Therapeutics Ceases Over 5 Million Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2493719652","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493719652?lang=en_us&edition=fundamental","pubTime":"2024-12-23 08:47","pubTimestamp":1734914869,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics Ltd. has announced the cessation of 5,816,912 securities due to t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-ceases-over-5-million-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-ceases-over-5-million-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139"],"gpt_icon":0},{"id":"2493271960","title":"Chimeric Therapeutics Issues Unquoted Equity Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2493271960","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493271960?lang=en_us&edition=fundamental","pubTime":"2024-12-23 08:47","pubTimestamp":1734914855,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics Ltd. announced the issuance of over 56 million unquoted equity se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-issues-unquoted-equity-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/chimeric-therapeutics-issues-unquoted-equity-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LENZ","EQR","BK4215","BK4139","BK4588"],"gpt_icon":0},{"id":"2493279179","title":"Aadi Bioscience Leads 3 Promising US Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2493279179","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493279179?lang=en_us&edition=fundamental","pubTime":"2024-12-23 08:09","pubTimestamp":1734912591,"startTime":"0","endTime":"0","summary":"As the U.S. stock market navigates a challenging week marked by encouraging inflation data yet overall losses, investors are exploring diverse opportunities to mitigate risk and capitalize on potential gains. Penny stocks, often associated with smaller or newer companies, continue to attract attention due to their potential for significant returns when backed by strong financial health. Despite being considered a niche area of investment today, these stocks can offer intriguing opportunities for those willing to explore beyond traditional large-cap options.Overview: Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, with a market cap of $83.55 million.Get an in-depth perspective on Aadi Bioscience's performance by reading our balance sheet health report here.Understand Aadi Bioscience's earnings outlook by examining our growth report.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NPWPwaqd_YNMPuUbekamwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/17286ad821a1799fbe520d67c5c5f1ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NPWPwaqd_YNMPuUbekamwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/17286ad821a1799fbe520d67c5c5f1ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aadi-bioscience-leads-3-promising-000951326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4166","SB","BK4139","IMRX","BK4503","BK4539","BABB","BK4209","BK4563","QD","AADI","BK4021"],"gpt_icon":0},{"id":"2493727524","title":"Prescient Therapeutics Gains FDA Approval for PTX-100 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2493727524","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493727524?lang=en_us&edition=fundamental","pubTime":"2024-12-23 07:47","pubTimestamp":1734911253,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics Limited (AU:PTX) has released an update. Prescient Therapeutics Limited has received FDA clearance to proceed with a Phase 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-gains-fda-approval-for-ptx-100-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/prescient-therapeutics-gains-fda-approval-for-ptx-100-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ"],"gpt_icon":0},{"id":"2493245378","title":"Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2493245378","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493245378?lang=en_us&edition=fundamental","pubTime":"2024-12-22 20:00","pubTimestamp":1734868805,"startTime":"0","endTime":"0","summary":"Whilst it may not be a huge deal, we thought it was good to see that the Prelude Therapeutics Incorporated  Founder, Krishna Vaddi, recently bought US$99k worth of stock, for US$0.93 per share. However, it only increased their shares held by 4.9%, and it wasn't a huge purchase by absolute value, either.Check out our latest analysis for Prelude Therapeutics. While Prelude Therapeutics insiders bought shares during the last year, they didn't sell. You can see the insider transactions  over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!But note: Prelude Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/krishna-vaddi-bought-4-9-120005287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","PRLD","BK4139","BK4505"],"gpt_icon":0},{"id":"2493921042","title":"What To Expect in the Markets This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2493921042","media":"Investopedia","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493921042?lang=en_us&edition=fundamental","pubTime":"2024-12-22 18:00","pubTimestamp":1734861600,"startTime":"0","endTime":"0","summary":"Markets are closed Wednesday for Christmas.On Christmas Eve, stock markets close at 1 p.m. ET and bond markets close at 2 p.m.Investors also will get reports on consumer confidence, new home sales, and initial jobless claims.Markets will trade on shortened hours during the Christmas holiday week, with all markets closed Wednesday for the holiday, and shortened trading hours on Christmas Eve.Investors will be watching for reports on consumer confidence, new home sales, durable goods orders, initial jobless claims, international trade, and retail inventories. Few earnings reports are scheduled.Durable goods orders New home sales Stock markets close at 1 p.m. ETBond markets close at2 p.m. ET. On Tuesday, investors will get Census Bureau data on new home sales and durable goods orders. The report on new home sales comes after similar data showed that existing home sales increased in November. The durable goods orders report will provide insight into the health of the U.S. manufacturing sec","market":"sg","thumbnail":"https://www.investopedia.com/thmb/mHNzv0TwlvN0iCYhStAfylR9e9A=/6684x4467/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1448939835-eb50af7b74c1476cafcd8690ff13d246.jpg","type":0,"news_type":0,"thumbnails":["https://www.investopedia.com/thmb/mHNzv0TwlvN0iCYhStAfylR9e9A=/6684x4467/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1448939835-eb50af7b74c1476cafcd8690ff13d246.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investopedia.com/what-to-expect-in-the-markets-this-week-8764806","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investopedia_highlight","symbols":["BK4139","AVXL","CFA.SI"],"gpt_icon":0},{"id":"2493212837","title":"Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493212837","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493212837?lang=en_us&edition=fundamental","pubTime":"2024-12-22 16:30","pubTimestamp":1734856200,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks.Vertex Pharmaceuticals  was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis  treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.But in recent weeks, Vertex stock has declined, and last week it lost nearly 12% in one trading session after an element from a clinical trial report disappointed investors. Meanwhile, Vertex is heading for two pieces of news in January that could be enormous for the company.Should you take advantage of recent losses to buy Vertex on the dip before the new year?Or is the recent clinical trial news a warning for investors?","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801725%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801725%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/22/should-you-buy-vertex-on-dip-before-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0823416689.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","VRTX","IE00B2B36J28.USD","LU1093756325.SGD","IE00BFTCPJ56.SGD","LU0234570918.USD","LU1585245621.USD","IE00B4R5TH58.HKD","BK4532","LU2362540622.SGD","LU0061475181.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","LU0320765992.SGD","LU2362541273.HKD","LU0889565916.HKD","LU1069344957.HKD","BK4567","IE00BJT1NW94.SGD","LU0109394709.USD","LU1559883803.SGD","IE00B19Z3581.USD","LU2456880835.USD","VERX","LU1035775433.USD","IE00B19Z9P08.USD","LU2236285917.USD","BK4093","LU2324357040.USD","BK4588","BK4533","LU2462157665.USD","LU2362541513.USD","LU0058720904.USD","LU0079474960.USD","IE00BZ9MQY76.HKD","LU0417517546.SGD","BK4585","IE0009355771.USD","IE0002141913.USD","BK4139","IE00BJJMRZ35.SGD","LU1093756168.USD","LU1430594728.SGD","LU0256863811.USD","LU0566484027.USD","CF","BK4023"],"gpt_icon":0},{"id":"2493263953","title":"Achieve Life Sciences, Inc. (NASDAQ:ACHV) down to US$131m market cap, but institutional owners may not be as affected after a year of 0.5% returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2493263953","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493263953?lang=en_us&edition=fundamental","pubTime":"2024-12-21 22:50","pubTimestamp":1734792607,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Achieve Life Sciences implies that they have significant influence...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-achv/achieve-life-sciences/news/achieve-life-sciences-inc-nasdaqachv-down-to-us131m-market-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACHV","BK4585","USJW.SI","IE00B3QW5Z07.USD","NQmain","BK4588","PSQ","TSYW.SI","NVIW.SI","IE00BGHQF748.EUR","QID","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","LU2210150020.SGD","TQQQ","QLD","MNQmain","BK4112","BK4139","USAW.SI",".IXIC","SQQQ"],"gpt_icon":1},{"id":"2493658812","title":"Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too","url":"https://stock-news.laohu8.com/highlight/detail?id=2493658812","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493658812?lang=en_us&edition=fundamental","pubTime":"2024-12-21 21:44","pubTimestamp":1734788682,"startTime":"0","endTime":"0","summary":"Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders would be excited to see that the share price has had a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-irwd/ironwood-pharmaceuticals/news/ironwood-pharmaceuticals-incs-nasdaqirwd-share-price-boosted","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QID","BK4112","NQmain","BK4139","BK4585","LU2210150020.SGD","USJW.SI","IE00BKPKM429.USD","IE00B64PRP62.GBP","MNQmain","IE00BGHQF748.EUR","SQQQ","LU2210149790.SGD","TSYW.SI","NDAQ","QLD","TQQQ","NVIW.SI","IE00B3QW5Z07.USD","PSQ","LU2095319765.USD","USAW.SI","IRWD",".IXIC","BK4588"],"gpt_icon":1},{"id":"2493253007","title":"Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2493253007","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493253007?lang=en_us&edition=fundamental","pubTime":"2024-12-21 21:43","pubTimestamp":1734788589,"startTime":"0","endTime":"0","summary":"Significant control over Aligos Therapeutics by retail investors implies that the general public has more power to influence management and governance-related decisions. 19% of Aligos Therapeutics is held by Institutions. A look at the shareholders of Aligos Therapeutics, Inc.  can tell us which group is most powerful. The group holding the most number of shares in the company, around 33% to be precise, is retail investors. Put another way, the group faces the maximum upside potential .As a result, retail investors collectively scored the highest last week as the company hit US$142m market cap following a 17% gain in the stock.Let's take a closer look to see what the different types of shareholders can tell us about Aligos Therapeutics.What Does The Institutional Ownership Tell Us About Aligos Therapeutics?Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiment","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aligos-therapeutics-inc-nasdaq-algs-134309108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","IE00B3QW5Z07.USD","BK4112","USJW.SI","BK4588","NQmain","LU2210150020.SGD","TSYW.SI","IE00BGHQF748.EUR","ALGS","BK4139","NVIW.SI","MNQmain","QID","TQQQ","IE00BKPKM429.USD","BK4505",".IXIC","QLD","BK4585","NDAQ","LU2095319765.USD","PSQ","IE00B64PRP62.GBP","SQQQ","LU2210149790.SGD"],"gpt_icon":1},{"id":"2493923070","title":"When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493923070","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493923070?lang=en_us&edition=fundamental","pubTime":"2024-12-21 20:59","pubTimestamp":1734785959,"startTime":"0","endTime":"0","summary":"We feel now is a pretty good time to analyse ESSA Pharma Inc.'s  business as it appears the company may be on the cusp of a considerable accomplishment. ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The US$71m market-cap company announced a latest loss of US$29m on 30 September 2024 for its most recent financial year result. Many investors are wondering about the rate at which ESSA Pharma will turn a profit, with the big question being “when will the company breakeven?”Below we will provide a high-level summary of the industry analysts’ expectations for the company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/essa-pharma-inc-nasdaq-epix-125919706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139",".IXIC","IE00BGHQF748.EUR","USJW.SI","IE00B3QW5Z07.USD","LU2210150020.SGD","TSYW.SI","TQQQ","BK4211","ESSA","IE00BKPKM429.USD","MNQmain","USAW.SI","PSQ","NDAQ","QLD","SQQQ","BK4112","BK4588","QID","IE00B64PRP62.GBP","LU2095319765.USD","BK4585","EPIX","NQmain","BK4195","LU2210149790.SGD","NVIW.SI"],"gpt_icon":1},{"id":"2493234991","title":"3 Fantastic Stocks That Could Enjoy a Santa Claus Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=2493234991","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493234991?lang=en_us&edition=fundamental","pubTime":"2024-12-21 18:48","pubTimestamp":1734778080,"startTime":"0","endTime":"0","summary":"Novo Nordisk should have an exciting year ahead.Vertex Pharmaceuticals seems likely to enjoy an end-of-year rebound.Santa Claus will soon be on his way delivering presents to kids around the world. But could the jolly gift-giver bring something for investors, too?","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801623%2Fsanta-claus-buggy-chart.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801623%2Fsanta-claus-buggy-chart.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/21/3-fantastic-stocks-that-could-enjoy-a-santa-claus/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4567","VERX","LU0256863811.USD","BK4007","IE0002270589.USD","BK4023","LU2324357040.USD","LU0289739699.SGD","LU1069344957.HKD","IE00B19Z3B42.SGD","LU1559883803.SGD","IE00BZ9MQY76.HKD","LU2236285917.USD","IE00B19Z9P08.USD","IE0002141913.USD","IE00B19Z3581.USD","BK4588","IE00BKVL7J92.USD","LU0566484027.USD","VRTX","BK4533","LU1035775433.USD","LU2362541513.USD","LU2237438978.USD","IE00B2B36J28.USD","LU2462157665.USD","IE00BZ1G4Q59.USD","IE00B19Z9Z06.USD","LU1093756168.USD","LU0061475181.USD","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU0109394709.USD","BK4585","BK4599","LU2417539215.USD","BK4139","LU0234570918.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BJT1NW94.SGD","NVO","LU0417517546.SGD","LU2456880835.USD","IE00B894F039.SGD","LU2362541273.HKD","LU0154236417.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD"],"gpt_icon":1}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}